Northern Trust
CGTX icon

Northern Trust’s Cognition Therapeutics CGTX Stock Holding History

Northern Trust’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Sell
168,686
-25,628
-13% -$29.8K ﹤0.01% 4053
2025
Q4 		$262K Buy
194,314
+49,073
+34% +$79.7K ﹤0.01% 3885
2025
Q3 		$196K Buy
145,241
+97,756
+206% +$133K ﹤0.01% 3990
2025
Q2 		$14.7K Hold
47,485
– – ﹤0.01% 4362
2025
Q1 		$20K Hold
47,485
– – ﹤0.01% 4339
2024
Q4 		$33.3K Hold
47,485
– – ﹤0.01% 4321
2024
Q3 		$22.3K Hold
47,485
– – ﹤0.01% 4325
2024
Q2 		$78.8K Hold
47,485
– – ﹤0.01% 4101
2024
Q1 		$86.4K Buy
47,485
+16,763
+55% +$34.6K ﹤0.01% 4117
2023
Q4 		$56.8K Hold
30,722
– – ﹤0.01% 4216
2023
Q3 		$44.2K Hold
30,722
– – ﹤0.01% 4195
2023
Q2 		$56.2K Buy
30,722
+1,538
+5% +$3.25K ﹤0.01% 4197
2023
Q1 		$57.8K Hold
29,184
– – ﹤0.01% 4229
2022
Q4 		$61.3K Buy
29,184
+15,068
+107% +$30.4K ﹤0.01% 4229
2022
Q3 		$27K Buy
+14,116
New +$29.4K ﹤0.01% 4483

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Northern Trust's CGTX Position: Q1 2026 in Review

Northern Trust reduced its Cognition Therapeutics (CGTX) stake by 13% in Q1 2026, selling an estimated $29.8K and leaving 168,686 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #4053.

Northern Trust first reported a position in CGTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $262K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Northern Trust held 168,686 shares of Cognition Therapeutics worth $128K as of Q1 2026.
  • Northern Trust sold 25,628 Cognition Therapeutics shares in Q1 2026, an estimated $29.8K.
  • Cognition Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4053 holding.
  • Northern Trust first reported a position in Cognition Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Northern Trust's Cognition Therapeutics position peaked at $262K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.